⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NTLA News
Intellia Therapeutics, Inc
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM
globenewswire.com
NTLA
Form 8-K
sec.gov
NTLA
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
globenewswire.com
NTLA
Intellia Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com
NTLA
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
globenewswire.com
NTLA
Growth Factors Market to Reach US$ 3.7 Bn by 2033, Expands Amid Rising Regenerative Medicine and Biopharmaceutical Innovation - Persistence Market Research
prnewswire.com
TMO
MRK
BIO
BIIB
AMGN
GILD
REGN
CRSP
NTLA
BMY
ABBV
AZN
NVS
PFE
JNJ
MRNA
BNTX
COR
STEM
ALGN
EXAS
MDLZ
BHC
CVS
UNH
CI
CNC
ELAN
ZTS
ISRG
QRVO
SWKS
AVGO
QCOM
INTC
MSFT
GOOG
AMZN
IBM
ORCL
CRM
ADBE
NFLX
DIS
MCD
SBUX
KO
PEP
PG
JPM
BAC
WFC
C
GS
MS
AXP
V
MA
HD
LOW
COST
TGT
WMT
BBY
CMCSA
VZ
T
XOM
CVX
SIRI
UBER
LYFT
NVDA
AMD
MU
AMAT
LRCX
ASML
ADI
TXN
QGEN
ILMN
VRTX
EDIT
BEAM
SRPT
ACAD
ALKS
MDT
SYK
DHR
GOOGL
U.S. Orphan Drug Market Report 2026: A $200 Billion Opportunity by 2031 - Indication, Company, Trial Phase, Marketed Status of 1400 Drugs, Drug Sales of 150 Drugs, Pricing and Dosage of 400 Drugs
globenewswire.com
BMY
GILD
JNJ
SNY
TAK
AMGN
AZN
LLY
MRK
PFE
REGN
VRTX
ABBV
ALNY
AMTX
BIIB
BMRN
CRSP
EXAS
INCY
IONS
JAZZ
NTLA
PTC
RGEN
XOM
Biohacking Market to Reach US$ 216.68 Billion by 2035 Driven by Metabolic Monitoring, Wearable Diagnostics, and Personalized Health Optimization | Astute Analytica
globenewswire.com
GOOG
ABT
DXCM
NVDA
CRSP
NTLA
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
NTLA
Cell and Gene Therapy in Numbers: $1.2B in Zolgensma Sales, $1.5B Yescarta Revenue, 46 FDA-Approved Therapies and $2B Strategic Deals
globenewswire.com
NVS
GILD
BMY
REGN
CRSP
NTLA
EDIT
BBIO
AZN
SGMO